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rently employed and identify opportunities for future research.METHODS: A com-
prehensive literature review of reference databases, conference abstracts, journals
and medical societies’ websites was performed. Publications reporting practice
management efficiency measures within ambulatory oncology practices and infu-
sion centers located in the United States were included. Search was limited to
English-language articles published between 2007 and 2010. All publication types
except continuing medical education materials and letters to the editor were ac-
cepted. Evidence quality was assessed with the Completeness of Reporting index
(CORE-14) instrument. RESULTS: Forty-seven references were accepted for inclu-
sion. Efficiency strategieswere classified into 7 distinct categories, each reported at
a similar frequency in the literature. Within and across these categories, common
themeswere standardization of care, use of best practices, and alignment between
quality and profitability initiatives. Most publications were recommendations
without a study design type (64%) and/or did not report quantifiable outcome data
(74%). Additionally, 21 publications did not define the practice type included, while
the remaining articles identified 12 different practice types. Consequently, appli-
cability is limited, since outcomes cannot be associated with a particular practice
type. Thirty-four publications were assigned a CORE-14 score of 0, indicating they
did not meet any criteria for methodological quality (mean score, 1.84).
CONCLUSIONS: Numerous efficiency methods are being touted in the literature,
but there is limited definitive data on the successfulness of these techniques. Fur-
ther research, of a high methodological caliber, is needed to support informed
decisions. Specifically, registries, surveys, and economic analyses would empower
oncologists and other oncology professionals with practical strategies to concur-
rently improve quality while maintaining profitability.
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A REVIEW OF EXPANDED ACCESS PROGRAMS (EAP) AND THEIR
CONSIDERATION BY HEALTH PLAN DECISION-MAKERS IN THE UNITED STATES
Khurdayan V, Rizzo M, Darity A, Mun D
Double Helix Consulting, New York, NY, USA
OBJECTIVES: After failing approved treatments, patients may receive investiga-
tional therapies through participation in a clinical trial or an expanded access
program (EAP). EAPs were established after the FDA decided to allow patients ac-
cess to investigational drugs for treatment purposes, and since then EAPs have
been set up in various therapeutic areas including oncology and infectious dis-
eases. No analysis, however, has been completed evaluating the use and value of
EAP data to US payers.METHODS:We analyzed the impact of EAP data on the US
payer decision making process in drug formulary positioning. Using examples of
different types of drug data including EAP, payers were asked how each type af-
fected drug coverage. After reviewing these results, we assessed payers’ awareness
of EAP relative to other data types to determine future impacts of EAP. Our study
allowed us to define the key value drivers for EAP trials and construct a value
matrix to evaluate future EAP opportunities. RESULTS: Payers in the United States
had a low awareness of EAP data driven by a lack of exposure to the data type but
mostly attributed to their sole use of RCT data in formulary decisions. While most
payers agreed that EAP data has little influence on their decision making process,
they did highlight factors that make EAP data more valuable to other stakeholders
and discussed how EAP data could improve product perception. CONCLUSIONS:
Our findings suggest that payers will not change their management approach and
formulary decisions based on EAP data. Payers realize that EAP datamight bemore
representative of the real world patient population than data from RCTs; however,
RCTs will remain the gold standard data source to evaluate agents for reimburse-
ment and formulary placement.
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OBJECTIVES: Conventional peginterferon-ribavirin antiviral treatment of chronic
hepatitis C virus (HCV) often leads to anemia and neutropenia. Based on US claims
data, we explored the incidence of both adverse events (AEs) and the associated
risk factors, and assessed the related erythropoietin/granulocyte colony stimulat-
ing factor (G-CSF) costs in daily clinical practice.METHODS: Commercially insured
patients with chronic HCV infection (ICD9 070.44,070.54,070.70,070.71) (all geno-
types), who initiated any combination of (peg)interferon and/or ribavirin were
identified in a large US claims database (Thomson 2006–2009). Time to first onset of
anemia and neutropenia was analyzed using Kaplan-Meier and Cox proportional
hazards regression. Anemia and neutropenia were defined based on ICD9-coding
(280-285,288) and/or prescription of erythropoietin and G-CSF. RESULTS: 3,935
chronic HCV-infected patients (mean age 51.1, 63%male) initiated HCV treatment.
86% of the patients initiated a combination of peginterferon and ribavirin. Mean
treatment duration was 245 days. Regardless of time on treatment, 32%/17% of the
cohort experienced anemia/neutropenia respectively. Age, female gender, Charl-
son co-morbidity index and liver cirrhosis were predictive for both AEs. 20.3%/
11.3% of the cohort received erythropoietin/G-CSF treatment respectively, on av-
erage for 131/126 days. Themean cost for the entire cohort tomanage both AEswas
$2,263 (erythropoietin) and $1,004 (G-CSF), which represents 12% of the overall
healthcare cost in the follow-up year for the entire cohort. Themajority of the costs
associated with AE-related treatments (58%/54%) occurred after week 24 of
therapy. CONCLUSIONS: Costs of managing anemia and neutropenia during HCV
treatment are considerable and often continued beyond 24 weeks of treatment.
New HCV treatment combinations allowing to shorten treatment up to 24 weeks,
may considerably reduce AE-related costs. This reduction may be most important
in treatment-naive genotype 1-infected patients, as the standard 48-week treat-
ment duration is longer compared with other genotypes.
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OBJECTIVES: The aim of this study was to explore the predictors of PPI dosing
regimen [once daily (QD) or twice daily (BID)] among patients with GERD.
METHODS: Using the HealthCore Integrated Research Database from 01/01/2004-
06/30/2009, GERD patients (ICD-9 codes 530.10-530.13, 530.19, 530.81, or 787.1x), 
18 years of age, having at least two PPI pharmacy claims (index date) from 01/01/
2005-06/30/2008 and continuous eligibility for 12months before and after the index
date were identified. Based on the PPI dosing regimen throughout the post-index
period, calculated as the ratio of quantity of medication dispensed/number of days
supply, GERD patients were classified as QD (ratio of 1.5) or BID (ratio of 1.5) PPI
users. Descriptive analyses were used to compare QD vs. BID PPI users and a mul-
tivariate logistic regressionwas conducted to assess independent predictors of BID
PPI use. RESULTS: This study included 248,386 GERD patients with a mean age of
52.8 (13.93) years and 56% were females. Based on the dosing regimen, 90%
(n222,759) were classified as QD and 10% (n25,627) as BID PPI users. Patients
with BID PPI dosing were significantly (all p0.0001) more likely to have Barrett’s
Esophagus (5% vs. 2%), baseline H2RA use (8.7% vs. 6.8%) and higher comorbidity
based on mean Deyo Charlson’s Comorbidity Index score (DCI) [0.89 (SD1.54) vs.
0.70 (SD1.37)]. Logistic regression results demonstrated that females [OR1.13
(95% CI1.08-1.18)], a diagnosis for Barrett’s Esophagus [OR2.08 (95% CI1.84-
2.36)], baseline H2RA [OR1.29 (95% CI1.20-1.39)] or PPI use [OR1.67 (95%
CI1.59-1.74)] and higher DCI score [OR1.09 (95%CI1.08-1.10)] were significant
(all p0.0001) predictors of BID PPI use. CONCLUSIONS: Patients who have a diag-
nosis of Barrett’s Esophagus, had baseline use of PPI or H2RA therapywere found to
be significant predictors of BID PPI dosing. Further studies understanding the dif-
ferences in clinical and economic outcomes based on PPI dosing regimen should be
undertaken.
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OBJECTIVES:The etiology of functional dyspepsia (FD) is debated. However, limited
published data exist on the associated co-morbid conditions with FD. This study
aimed to assess the odds (likelihood) of having FD based on the presence of other
objectively defined comorbid conditions.METHODS: Retrospective database anal-
ysis on a 4-year study period (2001-2004), using payroll data and adjudicated health
insurancemedical and prescription claims onmore than 300,000 employees. Study
comparisons were performed among employees with FD (ICD9 536.8x) and pro-
pensity-score-matched employees without FD (controls, matched on age, gender,
tenure with employer, marital status, race, region, salary, exempt status, and full-
time/part-time). Comorbid conditions were Specific Conditions (SC) defined by the
Agency for Healthcare Research and Quality (AHRQ). Subjects were classified as
having the condition by any claims with an ICD-9 code for the SC. The likelihood of
being in the FD cohort was modeled using logistic regression with indicator (1/0)
variables for 260 of the 261 specific AHRQ SCs (the FD-SC was not included). Odds
ratios 1.0 indicate the corresponding SC is more likely in the FD cohort, while
ratios1.0 indicate the SC is less likely to be in the FD cohort. RESULTS: The study
dataset contained 85,119 employees (1669 with FD and 83,450 matched controls
without FD). After controlling for all other AHRQ categories, the logistic regression
found that 19 specific categories weremore likely within the FD cohort, and 2 were
less likely within the FD cohort. Esophageal disorders, gastritis and duodenitis,
abdominal pain, and gout were most associated with having FD (odds ratios of 3.8,
3.7, 3.6, and 2.5, respectively). Only hypertension complications/secondary and
disorders of teeth and jaw were significantly negatively associated with FD.
CONCLUSIONS: This study identified varied comorbidities associated with FD di-
agnoses and may aid FD identification in future research.
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OBJECTIVES: Chronic hepatitis C, in its early stages, is commonly asymptomatic,
and many patients do not seek treatment. The current study attempts to identify
the characteristics of hepatitis C patients who initiate treatment for hepatitis C.
METHODS: This study is based on data from the 2009 and 2010 waves of the US
National Health andWellness Survey (N132,478), a cross-sectional database rep-
resentative of the adult US population. Patients who reported having been diag-
nosedwith hepatitis C by a physician were included for analysis (n1279). Patients
currently, or ever, taking a prescription medication for hepatitis C (n579) were
compared with patients who never took a prescription for hepatitis C (n700).
Group membership was predicted with a logistic regression model, including age,
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